Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab soravtansine ocular toxicity mitigation study in recurrent FRα-high ovarian cancer
2023-505617-24-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Incidence and severity of MIRV-related corneal TEAEs in asymptomatic patients. Planned start Jun 2024; status: authorised.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2023-505617-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505617-24-00.